ClinicalTrials.gg
CompletedNCT05760300Updated Sep 18, 2025Results posted

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

A Phase 1 interventional study of Bulevirtide (BLV) in Chronic Hepatitis D Infection, sponsored by Gilead Sciences. Completed at 9 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.

02

Conditions studied

  • Chronic Hepatitis D Infection

Browse trials for

03

In context

Hepatitis D, Chronic

43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.

This study's enrollment of 41 is below the median of 46 across 30 interventional studies indexed under Hepatitis D, Chronic.

Browse Hepatitis D, Chronic studies →

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

All Individuals:

  • (BMI) of at least ≥ 18.0 kg/m\^2 and ≤ 40.0 kg/m\^2 at screening.
  • No abnormalities on (ECG)
  • No known Liver Disease ( (AST) and Alanine Aminotransferase (ALT)) ≤ 3 x (ULN) at screening.

Individuals with Renal Impairment (RI):

  • Have RI classification at screening that has been unchanged during the 90 days prior to study drug dosing.
  • Estimated (eGFR) must be the following (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (Inker 2021)) based on serum creatinine as measured at the screening evaluation:

    • Severe RI (Groups A and B): eGFR ≥ 15 to ≤ 29 mL/min/1.73 m\^2
    • Moderate RI (Group C): eGFR ≥ 30 to ≤ 59 mL/min/1.73 m\^2
    • Mild RI (Group D): eGFR ≥ 60 to ≤ 89 mL/min/1.73 m\^2
  • ≥ 9 g/dL at screening.
  • Individuals with cardiovascular disease, hypertension, diabetes mellitus, hyperlipidemia, hypothyroidism, osteoporosis, and many others) may be included provided that these diseases/conditions are clinically stable.

Matched Control Individuals:

  • Have an eGFR of at least 90 mL/min/1.73 m\^2 (using the CKD-EPI equation) based on serum creatinine as measured at screening evaluation.
  • Matched for sex, age (± 10 years), and BMI (± 20%, 18.0 ≤ BMI ≤ 40.0 kg/m\^2) with the respective participant in the RI group.

Key Exclusion Criteria:

All Individuals:

  • Positive (HIV) test, surface antigen (HBsAg), or virus (HCV) antibody with detectable HCV viral ribonucleic acid (RNA) at screening.
  • Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with participant treatment, assessment, or compliance with the protocol.

Individuals with RI:

  • Recent history of reception of any blood or blood products or history of major bleeding within 4 weeks of dosing.
  • Positive test for drugs of abuse, including alcohol at screening or admission, with the exception of opioids and tetrahydrocannabinol (THC, marijuana) under prescription and verified by the investigator as for pain management.
  • Received treatment with trimethoprim or cimetidine or tenofovir prodrugs (tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)) (affects elimination of creatinine) or with competitors of renal tubular excretion (eg, probenecid, chronic high-dose nonsteroidal anti-inflammatory drugs) within 28 days of Day -1.
  • Received known nephrotoxic drugs (eg, aminoglycosides, amphotericin B, vancomycin, cidofovir, foscarnet, cisplatin, pentamidine, cyclosporine, tacrolimus, herbal remedies (eg, compounds with aristolochic acid)) within 28 days of Day -1.
  • Individuals requiring or anticipated to require dialysis within 90 days of study entry.
  • Serum albumin concentration \<25 g/L.
  • Uncontrolled treated/untreated hypertension (defined as a mean of 3 repeated measurements for systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg); current or documented history of repeated clinically significant hypotension or severe episodes of orthostatic hypotension (systolic blood pressure \<90 mmHg and/or diastolic blood pressure \<50 mmHg).

Matched Control Individuals:

  • Have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, with the exception of vitamins

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Group A: BLV 2 mg (Severe RI Group)

    Participants with severe renal impairment (RI) \[estimated glomerular filtration rate (eGFR) ≥ 15 to ≤ 29 mL/min/1.73 m\^2\] will receive bulevirtide (BLV) 2 mg, administered subcutaneously (SC), once daily (QD), for 6 days.

    Drug: Bulevirtide (BLV)

  • Experimental
    Group A: BLV 2 mg (Matched Control)

    Participants with normal renal function (matched control group) \[eGFR ≥ 90 mL/min/1.73 m\^2\] will receive BLV 2 mg, administered SC, QD, for 6 days.

    Drug: Bulevirtide (BLV)

  • Experimental
    Group B: BLV 10 mg (Severe RI Group)

    Participants with severe RI \[eGFR ≥ 15 to ≤ 29 mL/min/1.73 m\^2\] will receive BLV 10 mg, administered SC, QD, for 6 days.

    Drug: Bulevirtide (BLV)

  • Experimental
    Group B: BLV 10 mg (Matched Control)

    Participants with normal renal function (matched control group) \[eGFR ≥ 90 mL/min/1.73 m\^2\] will receive BLV 10 mg, administered SC, QD, for 6 days.

    Drug: Bulevirtide (BLV)

Interventions

  • Administered via subcutaneous (SC) injections

    Also known as: Hepcludex®, Myrcludex B

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter for Bulevirtide (BLV): AUCtau

    AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady state at Day 6.

    Time frame: Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose

  2. PK Parameter for BLV: Cmax ss

    Cmax is defined as the maximum observed concentration of drug at steady state at Day 6.

    Time frame: Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose

Secondary outcomes

  1. PK Parameter for BLV: AUC0-24

    AUC0-24 is defined as the concentration of drug over time between time 0 hour and time 24 hours.

    Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose

  2. PK Parameter for BLV: Cmax

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose

  3. PK Parameter for BLV: Tmax

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose

  4. PK Parameter for BLV: t1/2

    t1/2 is defined as the estimate of the terminal elimination half-life of the drug.

    Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose

  5. PK Parameter for BLV: CLss/F

    CLss/F is defined as the apparent clearance at steady state at Day 6. CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug per interval.

    Time frame: Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose

  6. PK Parameter for BLV: Vss/F

    Vss/F is defined as the apparent volume of distribution at steady state at Day 6.

    Time frame: Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose

  7. Pharmacodynamic (PD) Parameter for Total Bile Acids (BA): Cmax

    The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. Cmax is defined as the maximum observed concentration of total BA. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.

    Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose

  8. PD Parameter for Total BA: AUC0-24

    The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. AUC0-24 is defined as the concentration of total BA over time between time 0 hour and time 24 hours. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.

    Time frame: Days 1 and 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose

  9. PD Parameter for Total BA: NetAUC

    The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. NetAUC is defined as positive portion of area under the baseline-adjusted biomarker concentration versus time curve over the dosing interval. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.

    Time frame: Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose

  10. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or if the AE onset date was the same as the date of study drug start date then the AE onset time must have been on or after the study drug start time. If the AE onset time was missing when the start dates was the same, the AE was considered treatment emergent.and/or any AEs leading to premature discontinuation of study drug.

    Time frame: Up to 36 days

  11. Percentage of Participants Experiencing Laboratory Abnormalities

    A treatment-emergent laboratory abnormality was any value that was outside the reference range at any time post baseline up to and including the date of last study drug dose plus 30 days. Grading categories are determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening; Grade 5: Death. Participants with at least a 1 grade increased from baseline for an individual laboratory test where the maximum post baseline laboratory abnormality was grade 1 or higher and grade 3 or higher were reported. The maximum post baseline toxicity grade across all tests for an individual participant was used in analysis.

    Time frame: Up to 36 days

07

Results

Posted Sep 18, 2025

Participant flow

Participants were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestoneGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
Started10101110
Completed9101010
Not completed1010
Withdrew: Adverse event0010
Withdrew: Participant decision1000

Outcome measures

PrimaryPharmacokinetic (PK) Parameter for Bulevirtide (BLV): AUCtau

AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady state at Day 6.

Time frame:
Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose
Reported as:
Mean · hours(h)*nanograms per milliliter(ng/mL)
Pharmacokinetic (PK) Parameter for Bulevirtide (BLV): AUCtau
hours(h)*nanograms per milliliter(ng/mL)Group A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
Pharmacokinetic (PK) Parameter for Bulevirtide (BLV): AUCtau94.6 ± 29.8112 ± 32.61880 ± 6421810 ± 560
Statistical analysis
  • Group A: BLV 2 mg (Severe RI Group) vs Group A: BLV 2 mg (Matched Control) · Geometric least-squares mean ratio: 84.5 · 90% CI 60.1 to 119Parametric (normal theory) analysis of covariance (ANOVA) model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group B: BLV 10 mg (Severe RI Group) vs Group B: BLV 10 mg (Matched Control) · Geometric least-squares mean ratio: 104 · 90% CI 80.8 to 133Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
PrimaryPK Parameter for BLV: Cmax ss

Cmax is defined as the maximum observed concentration of drug at steady state at Day 6.

Time frame:
Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose
Reported as:
Mean · ng/mL
PK Parameter for BLV: Cmax ss
ng/mLGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
PK Parameter for BLV: Cmax ss15.0 ± 8.1114.6 ± 9.35311 ± 110307 ± 156
Statistical analysis
  • Group A: BLV 2 mg (Severe RI Group) vs Group A: BLV 2 mg (Matched Control) · Geometric least-squares mean ratio: 106 · 90% CI 63.6 to 175Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group B: BLV 10 mg (Severe RI Group) vs Group B: BLV 10 mg (Matched Control) · Geometric least-squares mean ratio: 108 · 90% CI 77.8 to 151Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
SecondaryPK Parameter for BLV: AUC0-24

AUC0-24 is defined as the concentration of drug over time between time 0 hour and time 24 hours.

Time frame:
Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose
Reported as:
Mean · h*ng/mL
PK Parameter for BLV: AUC0-24
h*ng/mLGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
PK Parameter for BLV: AUC0-2446.5 ± 13.353.4 ± 6.77843 ± 480876 ± 458
Statistical analysis
  • Group A: BLV 2 mg (Severe RI Group) vs Group A: BLV 2 mg (Matched Control) · Geometric least-squares mean ratio: 83.8 · 90% CI 67.4 to 104Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group B: BLV 10 mg (Severe RI Group) vs Group B: BLV 10 mg (Matched Control) · Geometric least-squares mean ratio: 100 · 90% CI 56.2 to 179Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
SecondaryPK Parameter for BLV: Cmax

Cmax is defined as the maximum observed concentration of drug.

Time frame:
Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose
Reported as:
Mean · ng/mL
PK Parameter for BLV: Cmax
ng/mLGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
PK Parameter for BLV: Cmax12.3 ± 4.9113.1 ± 6.49121 ± 86.2146 ± 83.9
Statistical analysis
  • Group A: BLV 2 mg (Severe RI Group) vs Group A: BLV 2 mg (Matched Control) · Geometric least-squares mean ratio: 96.5 · 90% CI 65.1 to 143Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group B: BLV 10 mg (Severe RI Group) vs Group B: BLV 10 mg (Matched Control) · Geometric least-squares mean ratio: 77.8 · 90% CI 42.7 to 142Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
SecondaryPK Parameter for BLV: Tmax

Tmax is defined as the time (observed time point) of Cmax.

Time frame:
Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
Reported as:
Median · h
PK Parameter for BLV: Tmax
hGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
Tmax (Day 1)1.00 (1.00 to 2.00)1.00 (0.500 to 2.00)4.00 (1.50 to 6.00)4.00 (1.50 to 9.00)
Tmax (Day 6)1.00 (1.00 to 3.00)1.50 (1.00 to 6.00)3.00 (2.00 to 4.03)3.00 (3.00 to 6.00)
SecondaryPK Parameter for BLV: t1/2

t1/2 is defined as the estimate of the terminal elimination half-life of the drug.

Time frame:
Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
Reported as:
Median · h
PK Parameter for BLV: t1/2
hGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
t1/2 (Day 1)2.47 (1.32 to 4.34)3.95 (1.20 to 6.66)2.86 (1.44 to 14.5)3.03 (1.53 to 8.23)
t1/2 (Day 6)3.98 (2.84 to 8.72)4.60 (2.31 to 7.87)2.79 (1.46 to 7.47)2.75 (1.44 to 3.78)
SecondaryPK Parameter for BLV: CLss/F

CLss/F is defined as the apparent clearance at steady state at Day 6. CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug per interval.

Time frame:
Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
Reported as:
Mean · milliliters per hour (mL/h)
PK Parameter for BLV: CLss/F
milliliters per hour (mL/h)Group A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
PK Parameter for BLV: CLss/F29.9 ± 13.419.1 ± 7.545.80 ± 1.696.09 ± 2.22
SecondaryPK Parameter for BLV: Vss/F

Vss/F is defined as the apparent volume of distribution at steady state at Day 6.

Time frame:
Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
Reported as:
Mean · mL
PK Parameter for BLV: Vss/F
mLGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
PK Parameter for BLV: Vss/F222 ± 175121 ± 69.424.4 ± 10.725.0 ± 14.2
SecondaryPharmacodynamic (PD) Parameter for Total Bile Acids (BA): Cmax

The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. Cmax is defined as the maximum observed concentration of total BA. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.

Time frame:
Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
Reported as:
Mean · micromoles per liter (µmol/L)
Pharmacodynamic (PD) Parameter for Total Bile Acids (BA): Cmax
micromoles per liter (µmol/L)Group A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
Cmax (Day 1)13.5 ± 8.588.54 ± 7.02110 ± 50.6121 ± 53.6
Cmax (Day 6)48.1 ± 35.458.2 ± 24.5168 ± 83.4207 ± 52.1
Statistical analysis
  • Group A: BLV 2 mg (Severe RI Group) vs Group A: BLV 2 mg (Matched Control) · Geometric least-squares mean ratio: 160 · 90% CI 97.2 to 263Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group A: BLV 2 mg (Severe RI Group) vs Group A: BLV 2 mg (Matched Control) · Geometric least-squares mean ratio: 65.9 · 90% CI 35.0 to 124Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group B: BLV 10 mg (Severe RI Group) vs Group B: BLV 10 mg (Matched Control) · Geometric least-squares mean ratio: 86.7 · 90% CI 53.3 to 141Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group B: BLV 10 mg (Severe RI Group) vs Group B: BLV 10 mg (Matched Control) · Geometric least-squares mean ratio: 72.6 · 90% CI 50.4 to 105Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
SecondaryPD Parameter for Total BA: AUC0-24

The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. AUC0-24 is defined as the concentration of total BA over time between time 0 hour and time 24 hours. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.

Time frame:
Days 1 and 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose
Reported as:
Mean · h*µmol/L
PD Parameter for Total BA: AUC0-24
h*µmol/LGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
AUC0-24 (Day 1)166 ± 109108 ± 58.81290 ± 6131450 ± 573
AUC0-24 (Day 6)581 ± 442705 ± 3242120 ± 10502710 ± 669
Statistical analysis
  • Group A: BLV 2 mg (Severe RI Group) vs Group A: BLV 2 mg (Matched Control) · Geometric least-squares mean ratio: 139 · 90% CI 87.8 to 221Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group A: BLV 2 mg (Severe RI Group) vs Group A: BLV 2 mg (Matched Control) · Geometric least-squares mean ratio: 66.8 · 90% CI 37.3 to 120Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group B: BLV 10 mg (Severe RI Group) vs Group B: BLV 10 mg (Matched Control) · Geometric least-squares mean ratio: 85.7 · 90% CI 54.5 to 135Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group B: BLV 10 mg (Severe RI Group) vs Group B: BLV 10 mg (Matched Control) · Geometric least-squares mean ratio: 70.3 · 90% CI 49.4 to 100Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
SecondaryPD Parameter for Total BA: NetAUC

The PD effect of BLV was evaluated on plasma BA in participants with RI compared to matched control participants with normal renal function. NetAUC is defined as positive portion of area under the baseline-adjusted biomarker concentration versus time curve over the dosing interval. The plasma bile acid panel includes 15 individual bile acids, and total BA is the sum of these 15 components.

Time frame:
Day 1: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours postdose; Day 6: Predose (≤ 30 minutes before dose), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, and 48 hours postdose
Reported as:
Mean · h*µmol/L
PD Parameter for Total BA: NetAUC
h*µmol/LGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
NetAUC (Day 1)54.9 ± 40.466.1 ± 57.61240 ± 5981400 ± 572
NetAUC (Day 6)496 ± 433662 ± 3302060 ± 10202660 ± 666
Statistical analysis
  • Group A: BLV 2 mg (Severe RI Group) vs Group A: BLV 2 mg (Matched Control) · Geometric least-squares mean ratio: 84.2 · 90% CI 32.7 to 217Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group A: BLV 2 mg (Severe RI Group) vs Group A: BLV 2 mg (Matched Control) · Geometric least-squares mean ratio: 58.0 · 90% CI 30.1 to 112Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group B: BLV 10 mg (Severe RI Group) vs Group B: BLV 10 mg (Matched Control) · Geometric least-squares mean ratio: 85.6 · 90% CI 54.1 to 135Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
  • Group B: BLV 10 mg (Severe RI Group) vs Group B: BLV 10 mg (Matched Control) · Geometric least-squares mean ratio: 69.6 · 90% CI 48.9 to 99.2Parametric (normal theory) ANOVA model appropriate for a parallel design with renal function group as a fixed effect was fitted to the natural log-transformed values of the multiple dose PK parameter under evaluation.
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or if the AE onset date was the same as the date of study drug start date then the AE onset time must have been on or after the study drug start time. If the AE onset time was missing when the start dates was the same, the AE was considered treatment emergent.and/or any AEs leading to premature discontinuation of study drug.

Time frame:
Up to 36 days
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)40.020.027.330.0
SecondaryPercentage of Participants Experiencing Laboratory Abnormalities

A treatment-emergent laboratory abnormality was any value that was outside the reference range at any time post baseline up to and including the date of last study drug dose plus 30 days. Grading categories are determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening; Grade 5: Death. Participants with at least a 1 grade increased from baseline for an individual laboratory test where the maximum post baseline laboratory abnormality was grade 1 or higher and grade 3 or higher were reported. The maximum post baseline toxicity grade across all tests for an individual participant was used in analysis.

Time frame:
Up to 36 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Laboratory Abnormalities
percentage of participantsGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
Grade 1 or Higher10090.010090.0
Grade 3 or Higher50.0045.50

Adverse events

Collected over All-Cause Mortality: Up to 420 days; Adverse Events: Up to 36 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: BLV 2 mg (Severe RI Group)0/10 (0%)0/10 (0%)4/10 (40%)
Group A: BLV 2 mg (Matched Control)0/10 (0%)0/10 (0%)2/10 (20%)
Group B: BLV 10 mg (Severe RI Group)0/11 (0%)1/11 (9.1%)2/11 (18.2%)
Group B: BLV 10 mg (Matched Control)0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent serious events
Most frequent serious events
EventGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
Cardiac failure congestiveCardiac disorders0/100/101/110/10
Most frequent other events
Showing 10 of 12
Most frequent other events
EventGroup A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)
EosinophiliaBlood and lymphatic system disorders1/100/100/110/10
NeutropeniaBlood and lymphatic system disorders1/100/100/110/10
Vessel puncture site haemorrhageGeneral disorders1/100/100/110/10
Urinary tract infectionInfections and infestations1/100/100/110/10
Alanine aminotransferase increasedInvestigations0/100/100/111/10
Lipase increasedInvestigations1/100/100/110/10
HyperkalaemiaMetabolism and nutrition disorders1/100/100/111/10
HypertriglyceridaemiaMetabolism and nutrition disorders0/101/100/110/10
HeadacheNervous system disorders0/101/101/111/10
DysmenorrhoeaReproductive system and breast disorders0/100/100/111/10

Baseline characteristics

The Safety Analysis Set included all participants who took at least 1 dose of study drug BLV.

Age, Continuous
Age, Continuous(years)Group A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)Total
Mean59 ± 15.155 ± 10.663 ± 11.157 ± 10.659 ± 11.9
Age, Customized
Age, Customized(Participants)Group A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)Total
Between 18 and 65 years695828
>=65 years416213
Sex: Female, Male
Sex: Female, Male(Participants)Group A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)Total
Female443314
Male668727
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)Total
Hispanic or Latino788831
Not Hispanic or Latino323210
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American20406
White81071035
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Group A: BLV 2 mg (Severe RI Group)Group A: BLV 2 mg (Matched Control)Group B: BLV 10 mg (Severe RI Group)Group B: BLV 10 mg (Matched Control)Total
United States1010111041
08

Study locations

9 sites
  • Velocity Clinical Research, New Smyrna Beach
    Edgewater, Florida 32132, United States
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
  • Floridian Clinical Research, LLC
    Miami Lakes, Florida 33016, United States
  • Global Clinical Professionals Research
    St. Petersburg, Florida 33705, United States
  • Genesis Clinical Research, LLC
    Tampa, Florida 33603, United States
  • Massachusetts General Hospital - Renal Associates Clinic
    Boston, Massachusetts 02114, United States
  • Nucleus Network
    Saint Paul, Minnesota 55114, United States
09

References and documents

Publications

  • Yehong Wang, Renee-Claude Mercier, Wildaliz Nieves, David Pan, Carrie Nielson, SteveTseng, Xu Zhang, Ann Qin, Parag Kumar. Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 2 mg Once Daily for 6 Days in Participants with Severe Renal Impairment and in Matched Control Participants with Normal Renal Function. The Liver Meeting, American Association for the Study of Liver Diseases; November 15-19, 2024; San Diego, CA. Abstract #1194.
  • Yehong Wang, Renee-Claude Mercier, Wildaliz Nieves, Carolina Machado, Steve Tseng, Yuejiao Jiang, Ann Qin, Teckla Akinyi, Parag Kumar, WED-313 Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 10 mg once daily for 6 days in participants with severe renal impairment and in matched control participants with normal renal function, Journal of Hepatology, Volume 82, Supplement 1, 2025, Page S824 (https://doi.org/10.1016/S0168-8278(25)02119-1).

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jul 2024, 16 months.

Results were first posted in Sep 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 8, 2023
StartActual
Mar 15, 2023
Primary completionActual
Jul 18, 2024
CompletionActual
Jul 23, 2024
Results first posted
Sep 18, 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05760300
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 8, 2023
Start date
Mar 15, 2023
Primary completion
Jul 18, 2024
Completion
Jul 23, 2024
Results posted
Sep 18, 2025
Last update
Sep 18, 2025

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bulevirtide

Start the discussion